- 21 September
-
On September 11–17, 2026, Ekaterinburg hosted the International Youth Festival, a large-scale event that brought together 10,000 young leaders from 191 countries. At the festival running under the motto «Follow Your Dream,» the Medsintez Plant presented its exhibition, showcasing the achievements of the Ural pharmaceutical industry in the field of import substitution.
- 18 September
-
The updated clinical guidelines for treatment of ARVI in children took effect on September 2, 2026. The document was developed by leading experts from the Union of Pediatricians of Russia, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and the Russian Society of Emergency Medical Care and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. It fundamentally shifts therapeutic approaches toward enhanced safety and minimal drug burden.
- 14 September
-
On September 3–4, 2026, Nizhny Novgorod hosted the 2nd Regional Endocrinological Congress: Challenges and Prospects of the Volga Region, with the active participation of the Medsintez Plant. As a strategic company, Medsintez Plant has been ensuring Russia's pharmaceutical security for 25 years. Company's exhibition booth showcased a range of hormonal medications for treatment of type 1 and type 2 diabetes, as well as drugs for infertility treatment through the IVF method.
- 04 September
-
More than twenty years ago, the Regiony Rossii (Regions of Russia, RR) magazine witnessed the birth of an innovative pharmaceutical production facility in Novouralsk, which had no analogues in the country. Today, the Medsintez Plant is a strategic asset in terms of national pharmaceutical security, a recognized industry leader, a National Champion, and a winner of prestigious awards. The secret behind the success of the Ural school of pharmaceuticals and biotechnology is explored in this article by RR.
- Home
- Cluster members
- Joint Stock Company «Uralbiopharm»
Joint Stock Company «Uralbiopharm»
Joint Stock Company «Uralbiopharm» stands as the preeminent manufacturer of contemporary pharmaceutical preparations and biologically active supplements in the Ural region.
Established in 1930, the enterprise formally commemorated its 95th anniversary on 1 October 2025.
Contemporary Profile of Uralbiopharm:
Designated as a systemically significant enterprise of the Russian Federation, actively participating in the national project «Labor Productivity»
Land area: 22,500 m²
Seven production facilities encompassing 3,280 m² of manufacturing space
Production of medicinal products for human medical and veterinary applications, alongside biologically active supplements
Participant in the import substitution initiative, undertaken in partnership with the Government of Sverdlovsk Oblast
An enterprise committed to perpetual advancement; since 2021, under the modernization and development program, acquisition of 13 units of packaging, labeling, and aggregation equipment has been completed
Exportation of pharmaceuticals to: the Republic of Uzbekistan, the Republic of Kazakhstan, the Kyrgyz Republic, Turkmenistan, the Republic of Tajikistan, the Republic of Belarus, Georgia, the Democratic People's Republic of Korea, and Mongolia
Contract manufacturing facility serving premier Russian pharmaceutical manufacturers
The enterprise has endorsed a strategic development plan for 2025–2032, encompassing:
The development and production of more than 70 novel pharmaceutical preparations and biologically active supplements
Construction of a state-of-the-art, technologically advanced production complex, tripling overall manufacturing capacity
Engagement in principal strategic federal initiatives pursuant to the «Pharma 2030» program
Establishment of scientific research and development operations in collaboration with Russia's leading specialized higher education institutions
Generation of over 150 new employment positions
Distinguishing Characteristics of JSC «Uralbiopharm» Products:
A substantial proportion of its preparations is incorporated into the List of Vital and Essential Drugs promulgated by the Russian Ministry of Health, affirming their paramount social significance
Rigorous quality control is maintained across all stages of production
The portfolio comprises both established medicinal products and innovative biologically active supplements and preparations designed to enhance immune function, alleviate stress, and sustain health amid viral infections
JSC «Uralbiopharm» furnishes an extensive array of high-demand pharmaceuticals that enable individuals to address acute and chronic pathologies, fortify immunological defenses, and elevate their overall quality of life.
Adress: 60, Kuibysheva st., Ekaterinburg, Sverdlovsk region, 620026
Теl. +7 343 254-01-93
Email: ubf@ubf.ru
Website: ubf.ru
Social media: https://vk.com/uralbiofarm
